{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:52Z","timestamp":1787020972574,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"General Program of Sichuan Natural Science Foundation","award":["2022NSFSC0846"],"award-info":[{"award-number":["2022NSFSC0846"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the role of adjuvant chemotherapy (CT) for resectable biliary tract cancer (BTC) is gradually recognized, the benefit of adjuvant chemoradiotherapy (CRT) is still controversial. Our study is designed to compare the prognosis of CRT versus CT in BCT patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinicopathologic characteristics of patients with operable gallbladder cancer (GBCA), intrahepatic bile duct cancer (IHBDC), or extrahepatic bile duct cancer (EHBDC) were obtained from the Surveillance, Epidemiology and End Results (SEER) database (2004\u20132015). Univariate and multivariate analyses were performed to identify prognostic factors for overall survival (OS). Selection bias were reduced by propensity-score matching (PSM). Kaplan\u2013Meier analysis was used to estimate the survival time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within 922 patients, 53.9% received adjuvant CRT, and 46.1% received adjuvant CT. Multivariate analysis showed age, primary tumor site, T stage, N stage, tumor size, number of removed lymph nodes, and treatment were independent risk factors for OS. Similar improvement of CRT on survival was identified by PSM in the matched cohort compared with CT (28.0\u00a0months vs. 25.0\u00a0months, p\u2009=\u20090.033), particularly in GBCA cohort (25.0\u00a0months vs. 19.0\u00a0months, p\u2009=\u20090.003). Subgroup analysis indicated CRT improved outcomes of patients with age\u2009\u2265\u200960, female,\u00a0lymph nodes positive,\u00a0tumor size\u2009\u2265\u20095\u00a0cm, and none removed lymph node diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjuvant CRT correlated with improved survival in patients with resected BTC compared with adjuvant CT, particularly in GBCAs. In addition, patients with age\u2009\u2265\u200960, female, lymph nodes positive, tumor size\u2009\u2265\u20095\u00a0cm, and none removed lymph node diseases may receive more benefits from adjuvant CRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-023-01299-w","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T03:02:50Z","timestamp":1693537370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database"],"prefix":"10.1186","volume":"28","author":[{"given":"Yueting","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyanling","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"10272","key":"1299_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, et al. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"suppl 5","key":"1299_CR2","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28\u201337.","journal-title":"Ann Oncol"},{"key":"1299_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100334","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun. 2021;27: 100334.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"1299_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ags3.12266","volume":"3","author":"S Matsukuma","year":"2019","unstructured":"Matsukuma S, et al. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg. 2019;3(4):378\u201389.","journal-title":"Ann Gastroenterol Surg"},{"key":"1299_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84: 101936.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1299_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1299_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015\u201327.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1299_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019;37(8):658\u201367.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1299_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202.","journal-title":"Br J Surg"},{"issue":"16","key":"1299_CR10","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1299_CR11","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, et al. SWOG S0809: A Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1299_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00066-012-0099-y","volume":"188","author":"D Habermehl","year":"2012","unstructured":"Habermehl D, et al. Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection\u202f: Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation. Strahlenther Onkol. 2012;188(9):795\u2013801.","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"1299_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijrobp.2021.05.012","volume":"111","author":"WI Chang","year":"2021","unstructured":"Chang WI, et al. The role of adjuvant chemoradiotherapy in nonhilar extrahepatic bile duct cancer: a long-term single-institution analysis. Int J Radiat Oncol Biol Phys. 2021;111(2):395\u2013404.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1299_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12876-020-1171-1","volume":"20","author":"H Kim","year":"2020","unstructured":"Kim H, Heo MH, Kim JY. Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer. BMC Gastroenterol. 2020;20(1):20.","journal-title":"BMC Gastroenterol"},{"key":"1299_CR15","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.1016\/j.ijrobp.2005.07.488","volume":"63","author":"M Baeza","year":"2005","unstructured":"Baeza M, et al. Post-operative adjuvant radiochemotherapy in the treatment of gallbladder cancer. Int J Radiat Oncol Biol Phys. 2005;63:S285\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00432-021-03524-7","volume":"147","author":"JH Im","year":"2021","unstructured":"Im JH, et al. Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. J Cancer Res Clin Oncol. 2021;147(8):2435\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7\u20138","key":"1299_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000517113","volume":"44","author":"W Wan","year":"2021","unstructured":"Wan W, et al. Adjuvant therapy in resected nonmetastatic stage II-IV gallbladder cancer: a generalized propensity score analysis. Oncol Res Treat. 2021;44(7\u20138):390\u20139.","journal-title":"Oncol Res Treat"},{"issue":"6","key":"1299_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.51.6.e1","volume":"51","author":"SA Khan","year":"2002","unstructured":"Khan SA, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(6):1\u20139.","journal-title":"Gut"},{"issue":"6","key":"1299_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.gassur.2005.12.002","volume":"10","author":"P Balachandran","year":"2006","unstructured":"Balachandran P, et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 2006;10(6):848\u201354.","journal-title":"J Gastrointest Surg"},{"issue":"35","key":"1299_CR20","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","volume":"29","author":"SJ Wang","year":"2011","unstructured":"Wang SJ, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;29(35):4627\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1299_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1245\/s10434-017-6139-1","volume":"25","author":"BH Kim","year":"2018","unstructured":"Kim BH, et al. Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25(1):255\u201364.","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01299-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:04:32Z","timestamp":1700327072000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01299-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01299-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}